Treatment Strategies in Myelodysplastic Syndromes

REFERENCES

• Parker J. E., Mufti G. J. The myelodysplastic syndromes: a matter of life or death. Acta Haematol. 2004; 111: 78–99
   PubMed Web of Science ®Google Scholar
• Daskalakis M., Nguyen T. T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957–64
   PubMed Web of Science ®Google Scholar
• Schmelz K., Wagner M., Dorken B., Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114: 683–95
   PubMed Web of Science ®Google Scholar
• Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96: 2240–5
   PubMed Web of Science ®Google Scholar
• Gersuk G. M., Beckham C., Loken M. R., et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. British Journal of Haematology 1998; 103: 176–88
   PubMed Web of Science ®Google Scholar
• Stifter G., Heiss S., Gastl G., Tzankov A., Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. European Journal of Haematology. 2005; 75: 485–91
   PubMed Web of Science ®Google Scholar
• Aul C., Giagounidis A., Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int. J. Hematol. 2001; 73: 405–10
   PubMed Web of Science ®Google Scholar
• Rollison D. E., Hayat M., Smith M., et al. First Report of National Estimates of the Incidence of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders from the U.S. SEER Program. ASH Annual Meeting Abstracts 2006; 108: 247
   Google Scholar
• Ma X., Does M., Raza A., Mayne S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007
   Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–99
   PubMed Web of Science ®Google Scholar
• Vardiman J. W., Harris N. L., Brunning R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292–302
   PubMed Web of Science ®Google Scholar
• Greenberg P., Cox C., LeBeau M. M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–88
   PubMed Web of Science ®Google Scholar
• Kaminskas E., Farrell A., Abraham S. et al. Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes. Clin. Cancer Res. 2005; 11: 3604–8
   Google Scholar
• New Treatment for Rare Bone Marrow Condition. FDA Consumer 2006; 40: 6
   Google Scholar
• New Treatment for Myelodysplastic Syndrome. FDA Consumer 2006; 40: 4
   Google Scholar
• A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br. J. Haematol. 1998; 103: 1070–4
   PubMed Web of Science ®Google Scholar
• Musto P., Falcone A., Sanpaolo G., et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br. J. Haematol. 2003; 122: 269–71
   PubMed Web of Science ®Google Scholar
• Garypidou V., Verrou E., Vakalopoulou S., et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br. J. Haematol. 2003; 123: 958
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 1995; 89: 67–71
   PubMed Web of Science ®Google Scholar
• Stasi R., Brunetti M., Terzoli E., Abruzzese E., Amadori S. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann. Oncol. 2004; 15: 1684–90
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 2003; 120: 1037–46
   PubMed Web of Science ®Google Scholar
• Stasi R., Abruzzese E., Lanzetta G., Terzoli E., Amadori S. Darbepoetin alfa for the treatment of anemic patients with low-and intermediate-1-risk myelodysplastic syndromes. Ann. Oncol. 2005; 16: 1921–7
   PubMed Web of Science ®Google Scholar
• Musto P., Lanza F., Balleari E., et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology. 2005; 128: 204–9
   PubMed Web of Science ®Google Scholar
• Mannone L., Gardin C., Quarre M. C., et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology. 2006; 133: 513–9
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Negrin R., Stein R., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 1997; 99: 344–51
   PubMed Web of Science ®Google Scholar
• Jadersten M., Montgomery S. M., Dybedal I., Porwit-MacDonald A., Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005; 106: 803–11
   PubMed Web of Science ®Google Scholar
• Musto P. Recombinant Erythropoietin and Survival in Myelodysplastic Syndromes. ASH Annual Meeting Abstracts 2005; 106: 2539
   Google Scholar
• Jadersten M., Malcovati L., Dybedal I., et al. Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need. ASH Annual Meeting Abstracts 2006; 108: 521
   Google Scholar
• Golshayan A. R., Jin T., Maciejewski J., et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. British Journal of Haematology. 2007; 137: 125–32
   PubMed Web of Science ®Google Scholar
• Greenberg P. L. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J. Natl. Compr. Canc. Netw. 2006; 4: 91–6
   PubMedGoogle Scholar
• Olivieri N. F., Nathan D. G., MacMillan J. H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N. Engl. J. Med. 1994; 331: 574–8
   PubMed Web of Science ®Google Scholar
• Malcovati L., Porta M. G.D., Pascutto C., et al. Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. J. Clin. Oncol. 2005; 23: 7594–603
   PubMed Web of Science ®Google Scholar
• Takatoku M., Uchiyama T., Okamoto S., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur. J. Haematol. 2007
   PubMed Web of Science ®Google Scholar
• Jensen P. D., Heickendorff L., Pedersen B., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br. J. Haematol. 1996; 94: 288–99
   PubMed Web of Science ®Google Scholar
• Leitch H. A., Goodman T. A., Wong K. K., et al. Improved Survival in Patients with Myelodysplastic Syndrome (MDS) Receiving Iron Chelation Therapy. ASH Annual Meeting Abstracts 2006; 108: 249
   Google Scholar
• FDA approves first oral drug for chronic iron overload, 11-9-2006. Ref Type: Internet Communication
   Google Scholar
• Kantarjian H., Beran M., Cortes J., et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006; 106: 1099–109
   PubMed Web of Science ®Google Scholar
• Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007; 109: 1395–400
   PubMed Web of Science ®Google Scholar
• Anderson J. E. Bone marrow transplantation for myelodysplasia. Blood Rev. 2000; 14: 63–77
   PubMed Web of Science ®Google Scholar
• Cutler C. S., Lee S. J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–85
   PubMed Web of Science ®Google Scholar
• Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006; 108: 836–46
   PubMed Web of Science ®Google Scholar
• Bibawi S., Abi-Said D., Fayad L., et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am. J. Hematol. 2001; 67: 227–33
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol. 1996; 14: 220–6
   PubMed Web of Science ®Google Scholar
• Molldrem J. J., Jiang Y. Z., Stetler-Stevenson M., et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. British Journal of Haematology 1998; 102: 1314–22
   PubMed Web of Science ®Google Scholar
• Sugawara T., Endo K., Shishido T., et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am. J. Hematol. 1992; 41: 304–5
   PubMed Web of Science ®Google Scholar
• Molldrem J. J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 2002; 137: 156–63
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y., Nakamura R., Wesley R., Wang Q. J., Barrett A. J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003; 102: 3025–27
   PubMed Web of Science ®Google Scholar
• Ravandi-Kashani F., Estrov Z., Ferrajoli A., et al. Phase I I Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome [abstract]. ASH Annual Meeting Abstracts 2006; 108: 4830
   Google Scholar
• Klausner J. D., Freedman V. H., Kaplan G. Thalidomide as an Anti-TNF-[alpha] Inhibitor: Implications for Clinical Use. Clinical Immunology and Immunopathology. 1996; 81: 219–23
   PubMedGoogle Scholar
• D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U S A. 1994; 91: 4082–5
   PubMed Web of Science ®Google Scholar
• Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001; 98: 958–65
   PubMed Web of Science ®Google Scholar
• Bouscary D., Legros L., Tulliez M., et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. British Journal of Haematology 2005; 131: 609–18
   PubMed Web of Science ®Google Scholar
• Musto P., Falcone A., Sanpaolo G., et al. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002; 87: 884–6
   PubMed Web of Science ®Google Scholar
• Strupp C., Germing U., Aivado M., et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002; 16: 1–6
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A., Colon-Otero G., Hoering A., et al. Thalidomide therapy in adult patients with myelodysplastic syndrome: a North Central Cancer Treatment Group phase II trial. Cancer. 2006; 107: 767–72
   PubMed Web of Science ®Google Scholar
• Richardson P. G., Blood E., Mitsiades C. S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–64
   PubMed Web of Science ®Google Scholar
• Zonder J. A. Thrombotic complications of myeloma therapy. Hematology Am. Soc. Hematol. Educ. Program. 2006; 348–55
   PubMedGoogle Scholar
• List A., Kurtin S., Roe D. J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 2005; 352: 549–57
   PubMed Web of Science ®Google Scholar
• List A., Dewald G., Bennett J., et al. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. N. Engl. J. Med. 2006; 355: 1456–65
   PubMed Web of Science ®Google Scholar
• List A. F., Dewald G. W., Bennett J. M., et al. Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q. ASH Annual Meeting Abstracts 2006; 108: 251
   Google Scholar
• Zonder J. A., Barlogie B., Durie B. G., et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403
   PubMed Web of Science ®Google Scholar
• Jones P. A., Taylor S. M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85–93
   PubMed Web of Science ®Google Scholar
• Silverman L. R., Demakos E. P., Peterson B. L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002; 20: 2429–40
   PubMed Web of Science ®Google Scholar
• Silverman L. R., McKenzie D. R., Peterson B. L., et al. Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006; 24: 3895–903
   PubMed Web of Science ®Google Scholar
• Silverman L. R., McKenzie D. R., Peterson B. L., et al. Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients leq 65 Years of Age. Blood 2005; 106: 2524
   Google Scholar
• Fabre C., Chermat F., Legros L., et al. Treatment of High Risk M DS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French A TU Program. ASH Annual Meeting Abstracts 2006; 108: 2664
   Google Scholar
• Lyons R. M., Cosgriff T., Modi S., et al. Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes [abstract]. ASH Annual Meeting Abstracts 2006; 108: 2662
   Google Scholar
• Rossetti J. M., Falke E., Shadduck R. K., et al. G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine. ASH Annual Meeting Abstracts 2006; 108: 4868
   Google Scholar
• Choi S. H., Byun H. M., Kwan J., Yang A. S. Hydroxyurea with Azacitidine or Decitabine in Combination Is Antagonistic on DNA Methylation Inhibition. ASH Annual Meeting Abstracts 2006; 108: 4303
   Google Scholar
• Wijermans P., Lubbert M., Verhoef G., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000; 18: 956–62
   PubMed Web of Science ®Google Scholar
• Wijermans P. W., Krulder J. W., Huijgens P. C., Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: S19–S23, Suppl 1
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Issa J P., Rosenfeld C. S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794–803
   PubMed Web of Science ®Google Scholar
• Issa J. P., Garcia-Manero G., Giles F. J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103: 1635–40
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–7
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G., Issa J. P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005; 23: 635–42
   PubMed Web of Science ®Google Scholar
• Gore S. D., Weng L. J., Figg W. D., et al. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. Clin. Cancer Res. 2002; 8: 963–70
   PubMed Web of Science ®Google Scholar
• Kuendgen A., Schmid M., Knipp S., et al. Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes. ASH Annual Meeting Abstracts 2005; 106: 789
   Google Scholar
• Garcia-Manero G., Yang H., Sanchez-Gonzalez B., et al. Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome. ASH Annual Meeting Abstracts 2005; 106: 2801
   Google Scholar
• Garcia-Manero G., Minden M., Estrov Z., et al. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS). J. Clin. Oncol. (Meeting Abstracts) 2006; 24: 6500
   Google Scholar
• Gojo I., Jiemjit A., Trepel J. B., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007; 109: 2781–90
   PubMed Web of Science ®Google Scholar
• Shen Z. X., Chen G. Q., Ni J. H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354–60
   Google Scholar
• Miller W. H., Jr., Schipper H. M., Lee J. S., Singer J., Waxman S. Mechanisms of Action of Arsenic Trioxide. Cancer Res. 2002; 62: 3893–903
   PubMed Web of Science ®Google Scholar
• Vey N., Bosly A., Guerci A., et al. Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study. J. Clin. Oncol. 2006; 24: 2465–71
   PubMed Web of Science ®Google Scholar
• Schiller G. J., Slack J., Hainsworth J. D., , Phase I I, et al. multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J. Clin. Oncol. 2006; 24: 2456–64
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Windle J. J., Von Hoff D. D. Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. J. Clin. Oncol. 1999; 17: 3631–52
   PubMed Web of Science ®Google Scholar
• Eric J., Feldman Jorge Cortes, Tessa L., Holyoake, et al. Continuous Oral Lonafarnib (Sarasar) for the Treatment of Patients with Myelodysplastic Syndrome [abstract]. Blood 2003; 102
   PubMedGoogle Scholar
• Fenaux P., Raza A., Mufti G. J., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 2007, blood-2006
   Web of Science ®Google Scholar
• Faderl S., Gandhi V., O'Brien S., et al. Clofarabine Is Active in Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 2006; 108: 2660
   Google Scholar
• Broliden P. A., Dahl I. M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006; 91: 667–70
   PubMed Web of Science ®Google Scholar
• Raza A., Reeves J. E., Feldman E. J., et al. Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities. ASH Annual Meeting Abstracts 2006; 108: 250
   Google Scholar